The stock has a 36-month beta value of 1.90. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ACET is 66.22M, and at present, short sellers hold a 5.20% of that float. On November 21, 2024, the average trading volume of ACET was 460.49K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ACET) stock’s latest price update
Adicet Bio Inc (NASDAQ: ACET)’s stock price has plunge by -6.11relation to previous closing price of 1.03. Nevertheless, the company has seen a -15.17% plunge in its stock price over the last five trading sessions. businesswire.com reported 2024-11-18 that REDWOOD CITY, Calif. & BOSTON–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC). “Solid tumors represent one of the highest unmet medical needs in oncology and have yet to benefit from th.
ACET’s Market Performance
Adicet Bio Inc (ACET) has experienced a -15.17% fall in stock performance for the past week, with a -36.37% drop in the past month, and a -37.20% drop in the past quarter. The volatility ratio for the week is 10.96%, and the volatility levels for the past 30 days are at 8.00% for ACET. The simple moving average for the past 20 days is -21.44% for ACET’s stock, with a -42.01% simple moving average for the past 200 days.
Analysts’ Opinion of ACET
Many brokerage firms have already submitted their reports for ACET stocks, with Guggenheim repeating the rating for ACET by listing it as a “Buy.” The predicted price for ACET in the upcoming period, according to Guggenheim is $7 based on the research report published on September 30, 2024 of the current year 2024.
ACET Trading at -28.92% from the 50-Day Moving Average
After a stumble in the market that brought ACET to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.35% of loss for the given period.
Volatility was left at 8.00%, however, over the last 30 days, the volatility rate increased by 10.96%, as shares sank -32.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.37% lower at present.
During the last 5 trading sessions, ACET fell by -15.17%, which changed the moving average for the period of 200-days by -69.68% in comparison to the 20-day moving average, which settled at $1.2311. In addition, Adicet Bio Inc saw -48.83% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACET starting from Kauffman Michael, who sale 5,900 shares at the price of $1.43 back on Jun 05 ’24. After this action, Kauffman Michael now owns 5,900 shares of Adicet Bio Inc, valued at $8,437 using the latest closing price.
ORBIMED ADVISORS LLC, the Director of Adicet Bio Inc, purchase 3,125,000 shares at $2.40 during a trade that took place back on Jan 25 ’24, which means that ORBIMED ADVISORS LLC is holding 7,526,359 shares at $7,500,000 based on the most recent closing price.
Stock Fundamentals for ACET
Current profitability levels for the company are sitting at:
- -9.96 for the present operating margin
- 0.62 for the gross margin
The net margin for Adicet Bio Inc stands at -9.14. The total capital return value is set at -0.57. Equity return is now at value -58.04, with -49.20 for asset returns.
Currently, EBITDA for the company is -136.53 million with net debt to EBITDA at 0.75. When we switch over and look at the enterprise to sales, we see a ratio of -0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.64.
Conclusion
To sum up, Adicet Bio Inc (ACET) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
